SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending after reporting substantial year-over-year revenue growth and expanded global approvals for its ANKTIVA cancer therapies in new markets and indications like lung cancer. The community is buzzing with talk of a potential short squeeze, encouraging buying dips, and anticipating significant long-term upside as the company broadens its global commercial footprint.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending due to its FDA approval of BYSANTI for bipolar I disorder and schizophrenia, a pivotal development underscored by its New Chemical Entity (NCE) status and patent protection until 2044. The community anticipates a significant re-rating and potential short squeeze, highlighting that this second recent FDA approval makes the company vastly undervalued compared to prior rejected buyout offers.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is seeing a significant downturn after its CagriSema weight-loss drug demonstrated slightly lower efficacy than a competitor in a recent trial, prompting community discussion on whether the market's reaction is an overcorrection despite NVO's strong financial position and other successful products.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after releasing positive Phase 2 trial data for its lead drug sonelokimab in axial spondyloarthritis, showing high efficacy and signs of disease modification ahead of its Investor Day. The community views this, coupled with a strong cash position and high short interest, as a significant re-rating catalyst, anticipating a substantial surge and potential for best-in-class market positioning.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending due to a sector-wide sell-off following Anthropic's Claude Code Security announcement, with community members divided on whether AI threatens CRWD's core endpoint and cloud security or reinforces the need for its advanced, AI-native platform.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as a top contender in the obesity drug market after a competitor's recent trial results underscored the potential superiority and tolerability of Viking's dual GLP-1/GIP agonist, VK2735. The community is actively discussing massive short interest, the advancing oral program, and intense speculation about an imminent buyout or significant partnership with a major pharmaceutical company seeking a leading position in the rapidly expanding metabolic space.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Arcellx Inc. is trending sharply higher after Gilead Sciences announced a definitive agreement to acquire the company for $7.8 billion, including a substantial premium per share. The community is actively discussing this major buyout as a validation of Arcellx's promising CAR T therapy, anito-cel for multiple myeloma, and a significant event that highlights acquisition potential within the biotech sector.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna (MRNA) is trending after the FDA reversed its initial refusal and agreed to review the company's seasonal flu vaccine application, igniting a significant short squeeze and renewed optimism for its broader mRNA pipeline, particularly in oncology and other respiratory diseases.

20/20 Biolabs, Inc. engages in development and commercialization of proteomics product line. Its products include One Test, PAULA's Test and BioCheck Suspisious Powder Testing Kit. The company was founded by Jonathan Cohen in May 2000 and is headquartered in Gaithersburg, MD.

20/20 Biolabs Inc

Recent IPO AIDX is trending due to extreme volatility and significant community debate, with some labeling it a 'pump and dump' anticipating further declines while others expect a major bounce, all within a broader sector experiencing pressure.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's Pizza is trending after its latest earnings revealed increased U.S. market share and continued international same-store sales growth, alongside a significant dividend hike, signaling strong operational execution. The community is discussing these results and an increased stake by notable investors as key drivers, highlighting the company's "Hungry for MORE" strategy and resilience in the restaurant sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dave (DAVE) Expected to Announce Quarterly Earnings on Monday

Dave (NASDAQ:DAVE) will be releasing its Q4 2025 earnings after the market closes on Monday, March 2. (View Earnings Report at...

Cipher Mining Stock Before Q4 Earnings: What's in the Offing?

CIFR's Q4 performance is likely to have been pressured by higher power costs, rising leverage and ongoing AI data center expansion efforts.

Stantec Gears Up to Report Q4 Earnings: What's in the Offing?

STN heads into Q4 2025 earnings with revenues expected to rise 11% on strong water, energy and infrastructure demand, though the model flags no clear beat.

Is CAC Optimization DAVE's Fuel to Its Profitability Engine?

Dave's optimized CAC and stepped-up marketing fuel 843,000 new members and powered triple-digit EBITDA and net income growth in 3Q25.

Dave (NASDAQ:DAVE) Rating Increased to Strong-Buy at Zacks Research

Zacks Research raised shares of Dave from a "hold" rating to a "strong-buy" rating in a research report on Monday...

Skillsoft Plummets 75% in a Year: Should You Hold or Fold the Stock?

SKIL shares plunge 75% in a year as GK revenues drop and liquidity concerns mount, but the AI push and cheap valuation raise a big question for investors amid the GK review now.

Principal Financial Group Inc. Acquires 12,555 Shares of Dave Inc. $DAVE

Principal Financial Group Inc. boosted its holdings in Dave Inc. (NASDAQ:DAVE - Free Report) by 22.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The...

Will DAVE INC (DAVE) Beat Estimates Again in Its Next Earnings Report?

DAVE INC (DAVE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

DAVE Stock Soars 79% in a Year: Should Investors Buy It Now?

Dave shares jump nearly 79% in a year, fueled by member growth, CashAI-driven credit quality, strong margins and a valuation below peers.

Keefe, Bruyette & Woods Begins Coverage on Dave (NASDAQ:DAVE)

Keefe, Bruyette & Woods assumed coverage on shares of Dave in a research note on Monday. They issued an "outperform" rating on the stock...

Dave, Inc. is a digital banking service. Its products include a budgeting tool to help members manage their upcoming bills to avoid overspending, cash advances through its flagship ExtraCash product to help members avoid punitive overdraft fees, a Side Hustle product, where Dave helps connect members with supplemental work opportunities, and Dave Banking, a modern checking account experience with valuable tools for building long-term financial health. The company was founded by Jason Wilk, Paras Chitrakar, and John Wolanin in October 2015 and is headquartered in Los Angeles, CA.

Current Price	$176.51
Prev Close	$178.24
Open	$175.49
Dividend Yield	0.00%
50-Day Moving Average	$196.53
Beta	2.12
Avg. Volume	537,292.55
PE Ratio	17.49

52-Week High	$286.45
52-Week Low	$65.46
Market Capitalization	$2.38B
EPS (Annual)	$4.19
Price to Book	8.18
Revenue Per Employee	$1.27M

DAVE
Dave Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DAVE News

DAVEDave Inc - Ordinary Shares - Class A